Deux ans de RCP nationale neurofibromatoses: émergence des anti-MEK
A. Jannic(Hôpitaux Universitaires Henri-Mondor), P. Wolkenstein(Université Paris-Est Créteil), Isabelle Aerts(Université Paris Sciences et Lettres), C. Hotz, S. Ferkal(Lyon 1 Université), O. Zehou, P. Combemale(Centre Léon Bérard), R. Gène(Hôpital Necker-Enfants Malades)
Cited by 0
Related Papers
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
|Genetics in Medicine|2021|766
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1
|American Journal of Medical Genetics|2000|241
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
|British Journal of Dermatology|2019|197
Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement
|Cytogenetics and Cell Genetics|2008|194